Testosterone Enanthate in South Asian Patients: Safety Profile Differences

Why South Asian Men Face a Different Risk Calculus on TRT

South Asian men carry a metabolic and cardiovascular burden that alters the safety equation for testosterone enanthate. The combination of visceral adiposity at lower BMI values, insulin resistance that appears decades earlier than in European populations, and distinct lipid profiles means that standard TRT monitoring protocols may miss early warning signs.

The Metabolic Syndrome Gap

The WHO and the International Diabetes Federation recognize that South Asian populations develop metabolic syndrome at lower anthropometric cutoffs. A South Asian man with a BMI of 24 kg/m² may carry the same cardiometabolic risk as a European man at BMI 30 kg/m² 1. This matters for TRT because testosterone enanthate affects glucose metabolism, lipid panels, and body composition. Clinicians who rely on standard BMI thresholds to assess cardiovascular risk before initiating testosterone therapy will systematically underestimate danger in South Asian patients.

Earlier Diabetes and Its Intersection With Testosterone

Type 2 diabetes appears roughly a decade earlier in South Asian populations compared to white Europeans, with a pooled incidence rate nearly four times higher even after adjusting for BMI 2. Testosterone replacement can improve insulin sensitivity in hypogonadal men. The T4DM trial (N=1,007) demonstrated that testosterone undecanoate reduced type 2 diabetes incidence by 40% over two years in men at high risk 3. But this trial enrolled predominantly white Australian men. Whether South Asian men see the same magnitude of metabolic benefit, or whether TRT interacts with their distinct insulin resistance phenotype differently, remains an open clinical question.

Cardiovascular Baseline Risk

The INTERHEART study found that South Asians experienced their first myocardial infarction a median 5-6 years younger than participants from other regions 4. Elevated lipoprotein(a), a genetically determined and largely treatment-resistant risk factor, runs 2-3 times higher in South Asian populations 5. The T-Trials showed that testosterone treatment increased coronary artery noncalcified plaque volume by 3.2% over 12 months in older hypogonadal men 6. For a patient population already carrying excess coronary risk, this signal demands attention.

Pharmacogenomic Variation That Alters Testosterone Metabolism

Testosterone enanthate is hydrolyzed to free testosterone, which is then metabolized through 5-alpha reduction, aromatization, and glucuronidation. Each of these pathways shows population-level variation relevant to South Asian men.

UGT2B17 Deletion Polymorphism

The UGT2B17 gene encodes an enzyme responsible for glucuronidating testosterone and its metabolites for renal excretion. A complete gene deletion (del/del genotype) occurs in 60-80% of East and South Asian individuals, compared to roughly 10-20% of Europeans 7. Men with the del/del genotype excrete testosterone glucuronide at significantly reduced rates. This has two clinical consequences. First, urinary testosterone-to-epitestosterone (T/E) ratios used in anti-doping are unreliable in this population. Second, and more relevant to clinical practice, testosterone clearance is slower, meaning standard doses may produce higher steady-state levels than predicted by studies conducted in predominantly European cohorts.

SRD5A2 and Aromatase (CYP19A1) Variants

The SRD5A2 gene, encoding 5-alpha reductase type 2, shows the V89L polymorphism at higher frequencies in Asian populations 8. This variant reduces enzyme activity by approximately 30%, leading to lower dihydrotestosterone (DHT) production per unit of circulating testosterone. The clinical implication: South Asian men on testosterone enanthate may convert less testosterone to DHT, potentially affecting androgenic endpoints like prostate stimulation, libido response, and hair follicle effects differently than European patients.

CYP19A1 (aromatase) polymorphisms also vary by population. Higher aromatase activity means more conversion of testosterone to estradiol. South Asian men with higher visceral adiposity already carry more aromatase-active tissue. When exogenous testosterone is added, estradiol levels can spike disproportionately 9. Monitoring estradiol at weeks 4 and 8 after initiation, rather than waiting for a 3-month check, is a reasonable adaptation for this population.

SHBG and Free Testosterone Calculations

Sex hormone-binding globulin (SHBG) levels are inversely correlated with insulin resistance. South Asian men with the metabolic syndrome phenotype (common even at normal BMI) tend to have lower SHBG, which inflates free testosterone calculations 10. A total testosterone level that appears borderline-low may actually represent adequate free hormone delivery. Prescribing testosterone enanthate based on total testosterone alone, without measuring SHBG and calculated free testosterone, risks treating a lab number rather than a clinical deficiency.

A Modified Monitoring Protocol for South Asian Men on Testosterone Enanthate

Standard TRT monitoring from the Endocrine Society (2018 guidelines) recommends baseline labs, then follow-up at 3, 6, and 12 months 11. For South Asian patients, the same framework applies but with expanded parameters and tighter intervals during the first 6 months.

Baseline Assessment Additions

Before starting testosterone enanthate, South Asian men should have the standard panel (total testosterone, free testosterone, LH, FSH, CBC, PSA, lipid panel, fasting glucose or HbA1c, liver function) plus three additions specific to their risk profile:

• Lipoprotein(a): a one-time measurement to quantify inherited coronary risk. Lp(a) above 50 mg/dL (or 125 nmol/L) flags a patient who needs coronary calcium scoring before TRT initiation.
• HOMA-IR or fasting insulin: standard fasting glucose may miss the insulin resistance that is already driving SHBG suppression and affecting free testosterone calculations.
• Estradiol (sensitive assay): baseline E2 before exogenous testosterone, especially in men with BMI above 23 kg/m² (the South Asian-adjusted threshold).

Monitoring Intervals

During months 1-6, check hematocrit, estradiol, and trough testosterone levels at weeks 4, 8, and 16 (rather than waiting until month 3 for the first post-initiation check). This compressed schedule catches polycythemia earlier. South Asian men may not show the expected dose-response curve if UGT2B17 activity is reduced, and trough levels running higher than expected at standard doses warrant a dose reduction rather than waiting for adverse events.

Cardiovascular Surveillance

The Endocrine Society guideline recommends against initiating testosterone in men who have had a cardiovascular event in the prior 6 months. For South Asian men with Lp(a) above 50 mg/dL, a coronary artery calcium (CAC) score above 100 Agatston units, or a 10-year ASCVD risk above 7.5% (using the race-adjusted pooled cohort equation), consider extending this caution window and involving a cardiologist in shared decision-making.

The TRAVERSE trial (N=5,246) found that testosterone replacement did not increase major adverse cardiovascular events compared to placebo in men aged 45-80 with preexisting or high-risk cardiovascular disease 12. This is reassuring. But the trial population was 70.7% white and included limited South Asian representation. Extrapolating the TRAVERSE safety signal to a population with a fundamentally different cardiovascular risk architecture requires caution.

Dosing Considerations: Start Low, Titrate Slow

The typical starting dose for testosterone enanthate in hypogonadal men is 100-200 mg intramuscularly every 1-2 weeks. For South Asian patients, several pharmacokinetic and metabolic factors favor a conservative start.

Why 100 mg Weekly Beats 200 mg Biweekly

A 200 mg injection every 14 days creates a wide peak-trough swing. The peak at 48-72 hours post-injection drives supraphysiologic testosterone levels, which are then aromatized to estradiol at rates proportional to adipose tissue mass. South Asian men with central adiposity (even at normal BMI) convert more testosterone to estradiol during these peaks. The trough at days 10-14 may drop into symptomatic hypogonadal range, creating a hormonal roller coaster.

Splitting the dose to 100 mg every 7 days (or even 80 mg every 7 days as a true starting dose) reduces peak-trough variation by roughly 50% 13. Smaller, more frequent dosing also reduces hematocrit elevation, as the sustained supraphysiologic peaks that stimulate erythropoiesis are blunted.

Subcutaneous Administration as an Alternative

A growing body of evidence supports subcutaneous testosterone enanthate injection as producing more stable serum levels than intramuscular dosing. A pharmacokinetic study (N=63) demonstrated that subcutaneous testosterone cypionate (pharmacologically near-identical to enanthate) produced equivalent total testosterone with 15-20% lower peak concentrations and a smoother absorption curve 14. For South Asian men who want to minimize cardiovascular and hematologic excursions, subcutaneous dosing at 50-80 mg twice weekly is worth discussing.

Polycythemia Risk and Hematologic Monitoring

Testosterone stimulates erythropoietin production and directly stimulates erythroid progenitor cells. Polycythemia (hematocrit above 54%) is the most common adverse effect of TRT, occurring in 3-18% of treated men depending on dose, route, and monitoring definition 15.

Population-Specific Considerations

South Asian men living at altitude (common in regions of Nepal, northern India, and Pakistan) may already have hematocrit values near the upper normal range. Baseline hematocrit above 48% in a sea-level South Asian man, or above 50% in a man living above 1,500 meters, should trigger a risk-benefit conversation before starting testosterone enanthate.

The mechanism is straightforward: exogenous testosterone increases hemoglobin by 1-2 g/dL on average. A man starting at hematocrit 49% on 200 mg every 2 weeks can reach 54% within 8-12 weeks. Dose reduction, increased injection frequency, or therapeutic phlebotomy are the standard interventions once hematocrit exceeds 54%.

When to Phlebotomize vs. Dose Adjust

Dr. Shalender Bhasin, principal investigator of the T-Trials, has stated: "The goal of testosterone therapy is to restore serum testosterone to the mid-normal range for young men, not to the upper end or above" 6. For South Asian men with rising hematocrit, the first intervention should be dose reduction and frequency adjustment, not reflexive phlebotomy. Phlebotomy depletes iron stores and creates a cycle of dependency if the underlying dose is not corrected.

Liver, Renal, and Prostate Safety in South Asian Men

Testosterone enanthate is not 17-alpha-alkylated and does not carry the hepatotoxicity risk of oral androgens. Liver safety on injectable testosterone enanthate is generally excellent across populations 11.

NAFLD Prevalence and Monitoring

Non-alcoholic fatty liver disease (NAFLD, now called MASLD) affects an estimated 30-40% of South Asian adults, compared to 25% globally 16. Testosterone deficiency itself is associated with hepatic steatosis, and testosterone replacement may improve liver fat content. A 48-week RCT (N=55) showed that testosterone undecanoate reduced hepatic fat fraction by 35% in men with type 2 diabetes and NAFLD 17. Baseline liver ultrasound or FIB-4 scoring is a reasonable addition to the South Asian TRT workup, both for risk stratification and to track potential liver fat improvement as a secondary benefit.

Prostate Safety

The Endocrine Society guideline recommends PSA monitoring at baseline, 3-6 months, and then annually. No ethnicity-specific adjustments to PSA thresholds exist for South Asian men. The incidence of prostate cancer in South Asian populations is lower than in African American or European populations, though detection rates are rising with improved screening access 18. A standard PSA monitoring protocol is appropriate, with digital rectal examination per urological guidelines.

Drug Interactions Relevant to South Asian Patients

South Asian men with type 2 diabetes and dyslipidemia are commonly prescribed metformin and statins. Neither interacts directly with testosterone enanthate at the pharmacokinetic level. Metformin may actually complement TRT by reducing insulin resistance and raising SHBG, which can help stabilize the free-to-total testosterone ratio.

Statins and testosterone share hepatic metabolism through CYP3A4. While simvastatin has the greatest CYP3A4 dependence, the interaction magnitude with testosterone enanthate is clinically negligible at standard TRT doses 19. No dose adjustment is needed for either drug.

Anticoagulants are the exception. Testosterone enanthate potentiates warfarin, increasing INR. South Asian men on warfarin for atrial fibrillation or valve disease require INR checks at 1 and 2 weeks after TRT initiation, with dose adjustment as needed 11.

Practical Takeaways for Clinicians and Patients

South Asian men considering testosterone enanthate should expect a workup that goes beyond the standard panel. Baseline Lp(a), HOMA-IR, and estradiol are additions that respect the population's distinct risk profile. Starting at 80-100 mg weekly (intramuscular or subcutaneous) rather than 200 mg biweekly reduces hormonal peaks that drive aromatization and polycythemia. Monitoring at weeks 4, 8, and 16 catches problems earlier than the standard 3-month first check. Hematocrit above 54% should trigger dose reduction first, not reflexive phlebotomy. And for men with Lp(a) above 50 mg/dL or CAC scores above 100, a cardiology consultation before TRT initiation is a clinical safeguard that standard guidelines do not yet mandate but that the data strongly support.